Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
STE
BuyPremium GrowerFLAGSTERIS plc · Healthcare · United States · $22.8B · Avg Vol: $142M/d
STERIS has quality Q70 and momentum exactly at M60 with a token buyback, but value at V46 is below the calibrated floor, and insiders sold 0.01% with no usable offsetting purchase, which is separately adverse.
COMPANY DESCRIPTION
STERIS plc is a global provider of infection prevention and other procedural products and services for healthcare, pharmaceutical, and research customers. Its competitive moat is built on its comprehensive portfolio of sterilization equipment, consumables, and services, strong regulatory compliance expertise, and established relationships within the healthcare sector, making it a market leader in infection control.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.2B | 4.5B | 5.1B | 5.5B | 5.9B | 8.9% | 6.0B | 6.4B | 6.8B | 6.9% |
| EPS | 2.50 | 1.07 | 3.83 | 6.24 | 7.97 | 33.6% | 8.19 | 8.76 | 9.60 | 9.7% |
| Shares | 100.1M | 98.6M | 98.9M | 98.3M | 97.8M | -2.3% | 97.5M | — | — | — |
| Debt | 3.3B | 3.2B | 3.4B | 2.2B | 2.1B | -10.7% | 2.0B | — | — | — |
| Equity | 6.5B | 6.1B | 6.3B | 6.6B | 7.2B | 2.4% | — | — | — | — |
| Op CF | 684.8M | 756.9M | 973.3M | 1.1B | 1.3B | 18.3% | 1.3B | — | — | — |
| Inv CF | -666.6M | -383.3M | -887.4M | 388.8M | -512.5M | — | — | — | — | — |
| Fin CF | 115.8M | -498.7M | -85.2M | -1.6B | -568.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of STE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| STE | STERIS plc(you) | $22.8B | 76 | Buy |
| ZBH | Zimmer Biomet Holdings, Inc. | $19.2B | 83 | Strong Buy |
| DXCM | DexCom, Inc. | $34.3B | 83 | Strong Buy |
| GEHC | GE HealthCare Technologies Inc. | $32.4B | 63 | Hold |
| BIO | Bio-Rad Laboratories, Inc. | $10.4B | 70 | Buy |
| EW | Edwards Lifesciences Corporation | $52.0B | 64 | Hold |
| GMED | Globus Medical, Inc. | $11.1B | 92 | Strong Buy |
| PEN | Penumbra, Inc. | $12.7B | 51 | Hold |
| ITGR | Integer Holdings Corporation | $4.3B | 68 | Buy |
| HAE | Haemonetics Corporation | $4.7B | 86 | Strong Buy |
Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.3%